Top

BMC Psychiatry

Published in:

Open Access 01-12-2011 | Research article

Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)

Authors: Concetta Crivera, Cherilyn DeSouza, Chris M Kozma, Riad D Dirani, Lian Mao, Wayne Macfadden

Published in: BMC Psychiatry | Issue 1/2011

Abstract

Background

Schizophrenia is a chronic mental health disorder associated with increased hospital admissions and excessive utilization of outpatient services and long-term care. This analysis examined health care resource utilization from a 24-month observational study of patients with schizophrenia initiated on risperidone long-acting therapy (RLAT).

Methods

Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE) was a 24-month observational study designed to examine real-world treatment outcomes by prospectively following patients with schizophrenia initiated on RLAT. At baseline visit, prior hospitalization and ER visit dates were obtained for the previous 12 months and subsequent hospitalization visit dates were obtained at 3-month visits, if available. The health care resource utilization outcomes measures observed in this analysis were hospitalizations for any reason, psychiatric-related hospitalizations, and emergency room (ER) visits. Incidence density analysis was used to assess pre-event and postevent rates per person-year (PY).

Results

The primary medical resource utilization analysis included 435 patients who had a baseline visit, ≥1 postbaseline visits after RLAT initiation, and valid hospitalization dates. The number of hospitalizations and ER visits per PY declined significantly (p < .0001) after initiation with RLAT. A 41% decrease (difference of -0.29 hospitalizations per PY [95% CI: -0.39 to -0.18] from baseline) in hospitalizations for any reason, a 56% decrease (a difference of -0.35 hospitalizations per PY [95% CI: -0.44 to -0.26] from baseline) in psychiatric-related hospitalizations, and a 40% decrease (-0.26 hospitalizations per PY [95% CI: -0.44 to -0.10] from baseline) in ER visits were observed after the baseline period. The percentage of psychiatric-related hospitalizations decreased significantly after RLAT initiation, and patients had fewer inpatient hospitalizations and ER visits (all p < .0001).

Conclusion

The results suggest that treatment with RLAT may result in decreased hospitalizations for patients with schizophrenia.

Trial Registration

ClinicalTrials.gov: NCT00246194

Available only for authorised users

Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J: The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005, 66: 1122-1129. 10.4088/JCP.v66n0906.CrossRefPubMed

Wyatt RJ, Henter I, Leary MC, Taylor E: An economic evaluation of schizophrenia--1991. Soc Psychiatry Psychiatr Epidemiol. 1995, 30 (5): 196-205.PubMedPubMedCentral

Kim B, Lee SH, Choi TK, Suh S, Kim YW, Lee E, Yook KH: Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry. 2008, 32 (5): 1231-1235. 10.1016/j.pnpbp.2008.03.012.CrossRefPubMed

Sun SX, Liu GG, Christensen DB, Fu AZ: Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin. 2007, 23 (10): 2305-2312. 10.1185/030079907X226050.CrossRefPubMed

Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K: Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003, 160 (6): 1125-1132. 10.1176/appi.ajp.160.6.1125.CrossRefPubMed

Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, Pretorius H, David AS: Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005, 15 (1): 111-117. 10.1016/j.euroneuro.2004.07.003.CrossRefPubMed

Fleischhacker W, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O: Treatment of schizophrenia with long acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003, 64: 1250-1257. 10.4088/JCP.v64n1017.CrossRefPubMed

Ehret MJ, Fuller MA: Long-acting injectable risperidone. Ann Pharmacother. 2004, 38 (12): 2122-2127. 10.1345/aph.1E085.CrossRefPubMed

Gaebel W, Schreiner A, Bergmans P, de Arce R, Rouillon F, Cordes J, Eriksson L, Smeraldi E: Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010, 35: 2367-2377. 10.1038/npp.2010.111. [published correction appears in Neuropsychopharmacology. 2011, 36:548]CrossRefPubMedPubMedCentral

10.

Conley RR, Kelly DL, Love RC, McMahon RP: Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry. 2003, 15 (1): 23-31.CrossRefPubMed

11.

Moore DB, Kelly DL, Sherr JD, Love RC, Conley RR: Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am J Health Syst Pharm. 1998, 55 (Suppl 2): S17-S19. 1998PubMed

12.

Fuller M, Shermock K, Russo P, Secic M, Dirani R, Vallow S, Flanders S: Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. J Med Econ. 2009, 12: 317-324. 10.3111/13696990903303902.CrossRefPubMed

13.

RISPERDAL® CONSTA® [Package Insert]: 2009, Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc

14.

Macfadden W, DeSouza C, Crivera C, Kozma CM, Dirani RD, Mao L, Rodriguez SC: Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results. BMC Psychiatry. 11: 167-

15.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A, e-STAR Study Group: Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the eSTAR database in Spain. Appl Health Econ Health Policy. 2008, 6: 41-53. 10.2165/00148365-200806010-00004.CrossRefPubMed

16.

Taylor M, Currie A, Lloyd K, Price M, Peperell K: Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J Psychopharmcol. 2008, 22: 128-131. 10.1177/0269881107084068.CrossRef

17.

Leal A, Rosillon D, Mehnert A, Jarema M, Remington G: Health resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf. 2004, 13: 811-816. 10.1002/pds.978.CrossRefPubMed

18.

Young CL, Taylor DM: Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand. 2006, 114: 14-20. 10.1111/j.1600-0447.2006.00766.x.CrossRefPubMed

19.

Spill B, Konoppa S, Kissling W, Maino K, Messer T, Heres S: Long-term observation of patients successfully switched to risperidone long-acting injectable: A retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs. Int J Psychiatry Clin Pract. 2010, 14: 53-62. 10.3109/13651500903311821.CrossRefPubMed

20.

Niaz OS, Haddad PM: Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand. 2007, 116: 36-46. 10.1111/j.1600-0447.2006.00980.x.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-244X/11/168/prepub

Title: Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)
Authors: Concetta Crivera
Cherilyn DeSouza
Chris M Kozma
Riad D Dirani
Lian Mao
Wayne Macfadden
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: BMC Psychiatry / Issue 1/2011
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/1471-244X-11-168

At a glance: The STEP trials

Springer Medicine

Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)

Abstract

Background

Methods

Results

Conclusion

Trial Registration

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Trial Registration

Please log in to get access to this content

Other articles of this Issue 1/2011

Familial liability, obstetric complications and childhood development abnormalities in early onset schizophrenia: a case control study

Adult attention deficit hyperactivity disorder is associated with asthma

Cocaine Addiction Treatments to improve Control and reduce Harm (CATCH): New Pharmacological Treatment Options for Crack-Cocaine Dependence in the Netherlands

Outcomes for depression and anxiety in primary care and details of treatment: a naturalistic longitudinal study

Repetition of suicide attempts across episodes of severe depression Behavioural sensitisation found in suicide group but not in controls

Mental health of female foreign spouses in transnational marriages in southern Taiwan